* Prothena Corporation PLC PRTA.OQ reported a quarterly
adjusted
loss of $1.08 per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of $-1.26. The mean expectation of nine analysts
for the quarter was for a loss of $1.04 per share. Wall Street
expected results to range from $-1.22 to -58 cents per share.
* Revenue rose 571.8% to $2.12 million from a year ago;
analysts
expected $7.53 million.
* Prothena Corporation PLC's reported EPS for the quarter
was a
loss of $1.08.
* The company reported a quarterly loss of $57.96 million.
* Prothena Corporation PLC shares had risen by 8.2% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Prothena
Corporation PLC is $44.00
This summary was machine generated from LSEG data February 21 at
12:49 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2024 -1.04 -1.08 Missed
Sep. 30 2024 -1.18 -1.10 Beat
Jun. 30 2024 -1.05 1.22 Beat
Mar. 31 2024 -1.20 -1.34 Missed